Business

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report

Recent advances in immuno-oncology, changes in lifestyle brought on by urbanisation, which predisposes populations to cancer, and the increased acceptability of targeted therapy are all contributing to the growth.

The global immuno-oncology clinical trials market was valued at USD 5.3 billion in 2020, with a compound annual growth rate (CAGR) of 13.6 percent predicted from 2021 to 2028.

COVID-19 has had a major impact on cancer research and clinical trials, affecting therapy and oncology patients in a variety of ways. Over 170 studies have been halted as a result of the virus, according to Evaluate Vantage’s research. Between February and May 2020, the epidemic disrupted 920 interventional oncology trials.

Immuno-Oncology Clinical Trials Market

Furthermore, clinical trial participation has become more difficult as a result of constraints such as transportation to trial sites or testing locations. In order to analyse the influence of COVID-19 on ongoing and future clinical research, IQVIA and the Cancer Research Institute cooperated to conduct a survey among oncology investigators. For the assessments, remote tools received great marks. Moreover, during the COVID-19 pandemic, various regional authorities gave rapid and thorough support for virtual tools and models, demonstrating that regulators saw patient-centric technology and approaches as viable solutions to this global problem.

 

Immuno-oncology trials make up more than a third of all cancer clinical trials. Small biotech and speciality pharma companies are expected to play a key role in the expansion. Immunotherapy improvements differ from cytotoxic chemotherapy in how they work, and these differences could affect dose, response evaluation, biomarker validation, combination therapy selection, and adverse event identification. Understanding and overcoming these roadblocks is critical for the success of immuno-oncology clinical trials and, eventually, market approval.

 

The most major improvements in immuno-oncology have come from treatments that focus on two targets: PD-1/PD-L1 and CTLA-4, which both negatively affect T-cell immunological activity to stimulate activation of the body’s own immune system. CAR-T (chimeric antigen receptor T-cell) therapy is another common immuno-oncology therapeutic option, in addition to PD-1/PD-L1 and CTLA-4 inhibitors. CAR-T therapies take a patient’s own T-cells, modify them to attack cancer, and then reintroduce them into the body.

 

Immuno-oncology (IO) continues to play an important role in oncology deal-making, accounting for 49% of drug licencing deals and 66% of total disclosed deal value. 15 of the 21 cancer drug licencing deals for over $1 billion were for IO assets, with 9 of those for multi-targeted techniques such bispecific antibodies and antibody-drug conjugates. The AstraZeneca/Daiichi Sankyo transaction was the largest medication licencing agreement in 2020.

 

Insights into the phases

In 2020, the phase III sector led the market, accounting for 53.1 percent of total revenue. This is partly due to the fact that Phase III costs around USD 59,500. Oncology trials also have a lower average number of participants. They are also the most expensive and involve a large number of people. According to the FDA, single-Phase III study participants have a lower average cost, so any fixed costs are spread out over a smaller group of persons. It has the most trials and trial participants (2,560, or roughly 40% of all industry-sponsored studies) (215,176, or almost 19 percent of all trial participants).

 

Over the projected period, the Phase II trial segment is expected to increase at the fastest rate of 19.8 percent. It’s also the most expensive stage, coming in second only to Phase III in terms of cost. This research is divided into two sections. The initial half of the process entails examining various dosages as well as efficacy trials, while the second half entails settling on a dose. Phase II is critical in clinical studies, especially in oncology.
Design Suggestions

Interventional trials led the market in 2020, accounting for 78.6 percent of the total revenue. There are around 3,042 active clinical trials exploring clinical-stage immune treatments, with a goal enrollment of 5,77, 076 patients. Interventional oncology studies are intended to show that some treatments are as effective as the current standard of care, but with significantly less morbidity and better outcomes for cancer patients.

 

The evidence for interventional oncology success is dominated by single-arm trials showing technical success or clinical efficacy. These research have resulted in the development of novel approaches, yet they are insufficient to uniformly modify clinical practise throughout healthcare systems. Interventional oncology studies are intended to show that some treatments are as effective as the current standard of care, but with significantly less morbidity and better outcomes for cancer patients.

 

Insights into Indications

The solid tumour segment led the immuno-oncology clinical trials market by indication in 2020, accounting for more than 56.0 percent of worldwide revenue. During the forecast period, the segment is expected to grow at the fastest rate of 13.6 percent. Solid tumours can appear anywhere in the body, including muscle, bone, and organs. Two main elements driving growth are unmet demand for cancer therapy and rising spending on cancer medication research and development. However, difficulties such as the expanding number of generic therapeutic products, the high cost of cancer therapy, and the approaching medicine patent cliff are holding back the solid tumour treatment market.
Regional Perspectives

North America dominated the market in 2020, accounting for 51.0 percent of total sales. The increased need for customised medicine-based new treatments is to blame for this increase. In addition, the government’s expanding financial support is moving the market in the region forward.

 

Throughout the projected period, Asia Pacific is expected to grow at the fastest rate of 14.7 percent. Immuno-oncology clinical trials are increasingly being conducted in Asia and Australia by biotechnology businesses. Immuno-oncology trials have been shown to be more effective against melanoma, lung cancer, bladder cancer, stomach cancer, and esophageal cancer. Over 600 locations across Asia Pacific have participated in the clinical development of IO medications, and hundreds more have received important experience managing clinical studies involving immunotherapies, including monotherapy and combo medicines. The majority of these trials take place in China, Australia, and South Korea.

 

India is on track to become a major hub for immuno-oncology clinical trials, and foreign sponsors should consider it for the use of immuno-oncology (IO) drugs such immune checkpoint inhibitors in clinical care and solid tumour clinical trials on a regular basis. Breast, oral, cervical, lung, stomach, and colorectal cancers are the most common types of cancer in India. Throughout the country, there are a number of government-funded and private cancer hospitals and research institutes with cutting-edge infrastructure that can manage multi-center immune-oncology clinical trials. As a result of these features, the country is extremely cost-effective. The Indian regulatory authority is speeding up the development of new medications and making immune-oncology clinical trials more accessible by establishing exact guidelines.

 

Insights into Key Companies and Market Share

Key market participants are pursuing various strategic initiatives such as new partnership agreements, collaborations, mergers and acquisitions, geographic growth, and product portfolio and production capacity strengthening in order to gain a competitive advantage.

 

BioNTech, for example, announced intentions to open its first mRNA manufacturing plant in Singapore in May 2021, expanding the company’s geographic foothold in Southeast Asia. Cutting-edge technologies and digital infrastructure would be used in the new mRNA synthesis plant. The following are some of the major players in the immuno-oncology clinical trials market:

 

Medpace

 

Novartis

 

Exscientia

 

Synergistic Health

 

AstraZeneca

Read Also: Pain Management Therapeutics Market

Offshore Wind Energy Market – Global Opportunity Analysis and Industry Forecast, 2022-2027

Offshore Wind Energy Market

COVID-19’s impact on the offshore wind market
COVID-19 has hampered offshore wind industry growth, as governments were required to apply lockdowns in the first half of 2020. Governments and municipal governments established strict restrictions, and all non-essential activity were halted. This had a negative impact on the offshore wind sector because there was less focus on its development.

The Global offshore wind market is expected to grow from an estimated USD 31.8 billion in 2021 to USD 56.8 billion by 2026, at a CAGR of 12.3% during the forecast period. Offshore wind turbines are increasingly being installed and is showing robust growth.

Furthermore, during the second quarter, production and supply chain delays were observed, posing a challenge to the offshore wind sector.

Offshore Wind Energy Market

Offshore Wind Energy Market

Market Trends in Offshore Wind

The offshore wind market is projected to be driven by rising global investments in renewable energy.

Due to causes such as the desire to minimise carbon emissions, the depletion of fossil fuels, climate change, and so on, there has been a considerable movement in the energy sector toward renewable and green energy. A number of government programmes are in place to aid the transition to greener energy. Many multinational corporations are taking steps to reduce their carbon footprint in order to contribute to a greener world and long-term sustainability. Equinor (Norway), for example, wants to cut its carbon emissions in half by 2050. The goal includes expanding its renewable energy companies, particularly offshore wind, which may reach 6,000 megawatts in six years and 16,000 megawatts in 15 years. Another example is the energy behemoth Total, which has agreed to sell a 51 percent stake in its Seagreen 1 offshore wind farm project to SSE Renewables. This project is expected to cost Total 70 million euros. Offshore wind, according to researchers, could generate USD 166 billion in new investments and USD 1.7 billion in new tax revenue for the US Treasury by 2022, while also supporting 80,000 employment annually by 2035.

 

Constraints: Expensive capital and logistical concerns

Offshore wind is one of the most promising and environmentally benign energy generation technologies available. Though it has a high capacity factor when compared to similar technologies like solar and onshore wind, its high capital cost prevents it from being implemented. Offshore wind turbines are prone to erosion since they operate in severe marine environments for decades. Even the most favourable characteristics, such as strong wind speeds, can become a disadvantage for offshore wind turbines. When the wind speed exceeds 25 m/s, the turbines, for example, tend to shut down. As the size of offshore wind farms has become larger, so have the obstacles of construction, transportation, installation, and operation. In general, logistics challenges are more difficult to overcome in offshore wind farms. Wind farms are typically placed far from the coast and are difficult to reach, particularly in poor weather. As a result, even the tiniest technical fault could be difficult and costly to resolve. Other difficult aspects of offshore wind deployment include resource characterization, grid connections and operation, and transmission infrastructure development, all of which are significantly easier in other technologies like solar and onshore wind. As a result, the worldwide offshore wind market is constrained by high capital expenditures and challenges related to operations, maintenance, transportation, and logistics.

 

Initiatives by governments and businesses to minimise carbon emissions are opportunities.

Because of dropping technology costs, a growing need to reduce CO2 emissions, and rising energy consumption in developing and underdeveloped countries, renewable energy demand will continue to climb. To meet the Paris Agreement’s aims, the share of renewables in annual global energy generation must climb from 25% to 86 percent by 2050, according to the International Renewable Energy Agency (IRENA). To do so, the world will need to invest USD 110 trillion in the sector by 2050, up from the USD 95 trillion expected by 2030. As a result of this shift, there will be a noticeable shift away from fossil fuels and toward renewable energy sources. Bloomberg BNEF estimates that USD 13.3 trillion will be invested on new power generation assets between 2019 and 2050, with 15,145 GW of carbon-free plants likely to be built. According to the BNEF, wind and solar will account for 50% of global electricity generation by 2050.

 

COVID 19’s Impact on Challenges

The wind power industry’s resilience and flexibility have been put to the test as a result of the worldwide economic downturn caused by the COVID-19 epidemic. The pandemic is still wreaking havoc on the wind power industry’s supply chain. Europe is one of the most important markets for offshore wind energy, and it’s also one of the hardest hit by COVID-19, which has hampered growth due to project delays. Because of the disruptions to European and worldwide trade, projects in the pipeline have been delayed, resulting in increased CAPEX. Offshore wind energy is expected to grow faster than onshore wind after the pandemic, according to the International Energy Agency.
In 2020, the turbine category will contribute the most to the offshore wind industry by component.

By component, the turbine category held the greatest proportion of the offshore wind market in 2020. The nacelle, rotors and blades, and tower segments of the offshore wind market are further divided. Turbines are mounted on the tower and are responsible for harvesting wind energy to generate electricity.

 

In 2020, the shallow water segment will be the largest contributor to the offshore wind market in terms of location.

In terms of location, the shallow water category accounted for the biggest proportion of the offshore wind market in 2020. This is where the majority of projects are carried out. This segment is recommended for the development of an offshore wine farm due to the presence of considerably less demanding weather and ease of maintenance. In addition, installing electrical infrastructure in shallow water is easier than installing a wind turbine. Because the wind speed available in shallow water is significantly lower, turbines with lower MW capacities are erected in this area.
Due to strong legislation and political commitment, Europe has built a market for offshore wind that is expected to continue to grow.

In 2020, Europe had the greatest proportion of the offshore wind market among all regions. The European market is broken down further into the United Kingdom, Germany, Denmark, Belgium, the Netherlands, Sweden, Finland, Ireland, and the rest of Europe. Several prominent offshore wind firms are based in Europe, including Siemens (Germany), Nordex SE (Germany), Vestas (Denmark), ABB (Switzerland), and others. Offshore wind technologies and offshore wind farm development have been pioneered in the European region. The European Wind Initiative (EWI), a wind energy R&D initiative created to take Europe’s wind industry to the next level, is supporting the development of offshore wind energy. The European Union’s countries are largely focused on rebuilding their old electrical infrastructure, and their governments are pushing renewable energy generation and establishing networks from generation to end-users to enable for efficient power and energy trading.

 

Siemens Gamesa (Spain), Vestas (Denmark), General Electric (US), and Shanghai Electric Wind Power are the market leaders in offshore wind (China).

Read Also: Immuno-Oncology Clinical Trials Market

Textile Coatings Market size is forecast to reach around $6 billion by 2025

Textile Coatings Market

A Market Overview of Textile Coatings
The process of putting a polymeric resin on one or both sides of a textile substrate is known as textile coating. Textile coating creates a new structure that combines the substrate’s and coating product’s qualities. It also protects the materials against a variety of external elements like heat, dust, soil, water, oil, and grease. As a result, the end product’s functionality and durability improve. It gives the final product features like fire resistance, anti-abrasion, anti-bacterial, and thermal insulation, as well as changing the overall appearance. PVC, PU, polyester, acrylics, SBR, natural rubber, silicon, and fluoropolymers are among the resins used to coat the textile substrate in textile coatings to create a variety of products for various uses. However, because PVC textile coating is hazardous to both humans and the environment, many producers have switched to PU as an alternative.
During the projected period, demand for textile coatings is expected to be fueled by the global growth of the apparel sector. The apparel industry is growing due to rising quality standards in rich nations and increased purchasing power and lifestyle changes in emerging countries. Textile coatings are also used to manufacture airbag materials and automotive upholstery for cars, buses, trains, lorries, and two-wheelers. As a result, the strongest automotive industry bases in Europe and Asia Pacific are likely to provide a consistent revenue stream for the Textile Coatings Market during the forecast period. Hoardings and signage, scaffolding nets, canopies and awnings, architectural membranes, conveyor belts, and construction worker safety jackets all use textile coatings. As a result, it is expected to be in great demand from the global building and construction industry. Textile coatings are also used to produce curtains, carpet backings, couch coverings, and pillow and cushion covers in the home furnishing business.

Textile Coatings Market

Textile Coatings Market

High revenue expenditure on home furnishing products in developed nations, rising disposable income, and improved living standards in developing regions are likely to produce a large home furnishing industry in the next years, positively impacting the Textile Coatings Market over the forecast period. Textile coatings have a wide range of uses in the healthcare business, including extracorporeal devices, implants, and medical gloves, and are likely to see strong demand during the assessment period. Textile coatings are also utilised in agriculture for fencing, crop protection coverings, sacks, and shade materials. Textile coatings are also used in geotextiles for landfill soil waterproofing.

Growing environmental worries about the negative effects of polymers used in textile coatings could stymie market expansion. The Textile Coatings Market is expected to be hampered by strict environmental regulations such as IPPC (Integrated Pollution Prevention and Control) and ETS (Emission Trading System).

Segmentation of the Market
The Textile Coatings Market is divided into four categories: coating type, coating process, end-use industry, and geography.
The Textile Coatings Market is divided into thermoplastics, thermosets, and others based on the kind of coating (silicon, fluoropolymers). Thermoplastics such as polyvinyl chloride (PVC), polyurethane (PU), acrylics, polyolefins, and others are utilised as raw ingredients for textile coatings. Styrene-butadiene rubber (SBR), natural rubber, and various thermosets are employed (nitrile rubber, butyl rubber, and others)

The Textile Coatings Market is divided into direct coating, direct roll coating, pad-dry-cure coating, foamed & crushed foam coating, hot melt extrusion coating, calender coating, and other coating methods based on the coating method.

The Textile Coatings Market is divided into clothing, transportation, building & construction, home furnishing, healthcare, and others based on the end-user industry (packaging, agricultural industry, geotextiles).

The Textile Coatings Market is divided into Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa based on region.
Analyses by Region

Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa are the five regions that make up the Textile Coatings Market. Due to growing home furnishing, construction, transportation, healthcare, agriculture, and packaging industries, Asia Pacific is expected to be the largest textile coating market in terms of market size due to relaxed investment norms, growing economy, and rising disposable income of the middle-class population. Because of the wide range of applications in clothing, healthcare, transportation, construction, and home furnishings, North America and Europe are projected to have continuous demand for PU-based textile coatings. Due to the booming tourism industry, the Middle East and Africa are projected to see increasing demand for textile coating from the building, clothing, and home furnishing sectors. Because of its low overall development, the Latin American market is likely to grow slowly.

Players to Watch
Covestro AG (Germany), Lubrizol Corporation (US), Huntsman International LLC (US), Solvay SA (Belgium), Clariant AG (Switzerland), BASF SE (Germany), Omnova Solutions Inc. (US), Sumitomo Chemical Company (Japan), Formulated Polymer Products Ltd. (UK), and Tanatex B.V. are some of the major players in the Textile Coatings Market (Netherlands).
September 2021 – Industry News IMCD China has signed a deal to purchase Aquatech Speciality (Guangzhou) Trading Co., Ltd. (“Aquatech”) and Aquatech Speciality (Shanghai) International Trading Co., Ltd. in China, according to IMCD N.V., a leading distributor of speciality chemicals and ingredients.

Aquatech has been providing aqueous solutions to the coatings, textile, and ink sectors since its inception in 2004. In 2020, the company earned more than RMB 51 million (about EUR 6.7 million), and ten new employees joined the IMCD China team. The company’s coatings business contributes to the portfolio of IMCD Coatings & Construction Business Group in China.

Andreas Igerl, Managing Director of IMCD China, said Aquatech’s value creation mindset aligns with IMCD’s vision of becoming a strong sustainable coatings solutions partner to its suppliers and customers.

Aquatech’s owner, Peter Shek, expressed his delight at the company’s inclusion in IMCD’s global network. Aquatech sees a bright future in the coatings sector thanks to their technical competence and global connections, as well as their local presence and capacity.

At Techtextil 2019, Bayer’s materials science division, Covestro AG, demonstrated sustainable breakthroughs in Insqin technology for aqueous Textile Coatings and water-based polyurethane dispersion. These advancements are being made to allow for biodegradable Textile Coatings.

Who is the target audience?
Manufacturers of Textile Coatings
Textile coatings traders and distributors
Institutes of research and development
Investors who might be interested
Suppliers of raw materials
Nationalized research facility

Read alos:Rare Gases Market

Global Antiseptics and Disinfectants Market to Reach USD 13.3 Billion By 2028

Global Antiseptics And Disinfectants Market Trends and Demand

World Market for Antibiotics and Disinfectants includes a Market overview, market segments, new developments, and the competitive landscape are just a few of the topics covered in the report. Also included are chapters on the study’s strategic recommendations, key company analysis, and an examination of the market’s potential opportunities, pricing analysis, and gap analysis. The global antiseptics and disinfectants market is growing due to the increasing prevalence of hospital-acquired infections and the increasing cost of healthcare.

Global Antiseptics And Disinfectants Market Trends and Demand

Opportunities for Growth

Domestic use and personal cleanliness are becoming increasingly popular among people.

Various types of disinfectants are available for use in the house and are frequently utilized in domestic settings. The surface disinfectant is regarded as a crucial measure to avoid COVID-19 in homes and communal places. It is recommended by the CDC that dwellings be disinfected in order to minimize the virus’s ability to survive in the environment. Antiseptic and disinfectant use is on the rise as a means of preventing the spread of disease. Antimicrobial chemicals, such as alcohols, chlorhexidine, hexachlorophene, iodine, and quaternary ammonium compounds, reduce the quantity of microorganisms in the environment.

Antiseptic and disinfectant demand rises as a result of a pandemic.

The new coronavirus outbreak is linked to high infection rates and has spread swiftly across the globe as a result of the pandemic (COVID-19). Preventive efforts are being made by the government and the medical community to stop the spread of COVID-19. As a result of the outbreak, there has been an increase in the demand for antiseptics and disinfectants.

The Effect of COVID-19 on the World Market for Antibiotics and Disinfectants

The global antiseptics and disinfectants market was positively affected by the COVID-19 epidemic. Infection control and clinical management were in high demand following the outbreak. The FDA is able to improve the availability of antiseptics and disinfection devices by accepting critical health issues. Viral exposure can be reduced by the widespread availability of disinfectants or antiseptics.

An Environment of Struggle

Johnson & Johnson, Becton, Dickinson And Company, Procter & Gamble Co, 3M Co., Bio-Cide International, Inc., Ecolab, Inc., Novartis AG, and Cardinal Health are just a few of the major players in the global antiseptics and disinfectants market. They all play a significant role in the industry’s expansion and development. Innovative product development, joint ventures, mergers and acquisitions, and geographic expansions are some new strategies being used by industry players to remain competitive in the worldwide market.

In July 2020, PVP-I antiseptic skin preparation with sterile solution will be commercially accessible in the United States thanks to Becton, Dickinson, and Company and their PurPrep skin preparation. The product is a single-use antiseptic skin preparation made with isopropyl alcohol and povidone-iodine that is completely sterile. Fluid-resistant, film-forming polymer generates drape adherence and an antimicrobial barrier that iodine can bind to the skin for residual antibacterial activity in the product’s formulation.

Becton, Dickinson and Company announced in April 2019 that the FDA had approved BD ChloraPrep, a sterile solution for skin preparation. It is the only commercially available, totally sterile preparation of chlorhexidine gluconate antiseptic skin in the United States. The organization is always looking for new ways to help people and improve their health. To minimize the potential for internal contamination, the organization makes a point of supplying sterile solutions.

Nowhere else can you find this kind of information.

You will be less likely to fall behind in your knowledge or miss out on opportunities if you use our new report title. See if our work can help you with your research, analysis, and decision-making. Anyone interested in commercial evaluations of the antiseptic and disinfectant markets, as well as major firms, should read this report by Visiongain. You’ll discover statistics, patterns, and forecasts.

Read More: Global Aloe Vera Extracts Market Is Expected to Grow At a CAGR of About 7.8%